Intervention of Shugan Xiaozhi Decoction on Nonalcoholic Fatty Liver Disease via Mediating Gut-Liver Axis

被引:5
|
作者
Yang, Huili [1 ,2 ]
Feng, Lian [1 ,2 ]
Xu, Linyi [1 ,2 ]
Jiang, Dansheng [1 ,2 ]
Zhai, Fenfen [3 ]
Tong, Guangdong [1 ]
Xing, Yufeng [1 ]
机构
[1] Shenzhen Tradit Chinese Med Hosp, Hepatol Dept, Shenzhen 518033, Guangdong, Peoples R China
[2] Guangzhou Univ Chinese Med, Clin Med Coll 4, Shenzhen 518033, Guangdong, Peoples R China
[3] Shenzhen Futian Ctr Chron Dis Control, Shenzhen 518048, Guangdong, Peoples R China
关键词
APOLIPOPROTEIN-B; PPAR-ALPHA; MICROBIOTA; METABOLISM; PROGRESSION; DEFICIENCY; DISORDERS; BACTERIA; RECEPTOR; OBESITY;
D O I
10.1155/2022/4801695
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Nonalcoholic fatty liver disease (NAFLD) is a chronic liver disease with an increasing incidence rate but few therapies. Shugan Xiaozhi decoction (SX) has demonstrated beneficial effects in treating NAFLD with an unclear mechanism. This study was aimed at investigating the therapeutic mechanism of SX on high-fat diet-induced NAFLD rats via the gut-liver axis. Hepatic steatosis and integrity of intestinal mucosa in NAFLD rats were assessed by histopathological staining. The level of lipid and inflammation were estimated by enzyme-linked immunosorbent assay. Western Blotting was used to detect apolipoprotein (apo) B48 expression. 16S rRNA analysis was used to measure the changes of gut microbial composition after SX treatment. The expressions of zona occludens 1 protein (ZO-1), occludin, and secretory immunoglobulin A (sIgA) in the colon were detected by immunostaining to investigate the intestinal barrier function. Our study found that SX reduced hepatic steatosis, the levels of alanine aminotransferase, aspartate aminotransferase, total cholesterol, and triglyceride and apoB48 expression but increased peroxisome proliferator activated receptor alpha (PPAR alpha) level. Moreover, SX altered the diversity of gut microbiota, upregulating the relative abundance of f_Prevotellaceae, while downregulating f_Bacteroidales_ S24-7, f_Lachnospiraceae, f_Ruminococcaceae, f_Erysipelotrichaceae, and f_Desulfovibrionaceae. By increasing the expression of ZO-1 and occludin and decreasing the level of proinflammatory factors, including sIgA, lipopolysaccharide, tumor necrosis factor-alpha, interleukin-1 beta, monocyte chemotactic protein-1, and transforming growth factor-beta 1, SX improved intestinal mucosal integrity and barrier function. Our study illustrated that the gut-liver axis was a potential way for SX to ameliorate NAFLD, that is, by regulating the expression of PPAR alpha, apoB48, and modulating gut microbiota to protect the intestinal barrier function, and thus alleviate lipid deposition and inflammatory response in the liver.
引用
下载
收藏
页数:15
相关论文
共 50 条
  • [1] Research Progress on Gut-Liver Axis Mediated Nonalcoholic Fatty Liver Disease and Its Nutritional Intervention
    Xu Y.
    Hu Y.
    Xu J.
    Huang X.
    Huang K.
    He X.
    Shipin Kexue/Food Science, 2023, 44 (03): : 366 - 375
  • [2] Nonalcoholic Fatty Liver Disease and the Gut-Liver Axis: Exploring an Undernutrition Perspective
    Bauer, Kylynda C.
    Littlejohn, Paula T.
    Ayala, Victoria
    Creus-Cuadros, Anna
    Finlay, B. Brett
    GASTROENTEROLOGY, 2022, 162 (07) : 1858 - +
  • [3] Bile Acid Receptors and the Gut-Liver Axis in Nonalcoholic Fatty Liver Disease
    Xue, Rui
    Su, Lianyong
    Lai, Shengyi
    Wang, Yanyan
    Zhao, Derrick
    Fan, Jiangao
    Chen, Weidong
    Hylemon, Phillip B.
    Zhou, Huiping
    CELLS, 2021, 10 (11)
  • [4] Volatile Oil of Amomum villosum Inhibits Nonalcoholic Fatty Liver Disease via the Gut-Liver Axis
    Lu, Shanhong
    Zhang, Ting
    Gu, Wen
    Yang, Xingxin
    Lu, Jianmei
    Zhao, Ronghua
    Yu, Jie
    BIOMED RESEARCH INTERNATIONAL, 2018, 2018
  • [5] The gut-liver axis in nonalcoholic fatty liver disease: molecular mechanisms and new targets
    Schneider, Kai Markus
    Trautwein, Christian
    GASTROENTEROLOGE, 2020, 15 (02): : 112 - 122
  • [6] The Gut-Liver Axis in Nonalcoholic Fatty Liver Disease: Another Pathway to Insulin Resistance?
    Vanni, Ester
    Bugianesi, Elisabetta
    HEPATOLOGY, 2009, 49 (06) : 1790 - 1792
  • [7] Gut-liver axis and fibrosis in nonalcoholic fatty liver disease: An input for novel therapies
    Frasinariu, Otilia E.
    Ceccarelli, Sara
    Alisi, Anna
    Moraru, Evelina
    Nobili, Valerio
    DIGESTIVE AND LIVER DISEASE, 2013, 45 (07) : 543 - 551
  • [8] Intestinal dysbiosis in nonalcoholic fatty liver disease (NAFLD): focusing on the gut-liver axis
    Han, Hui
    Jiang, Yi
    Wang, Mengyu
    Melaku, Mebratu
    Liu, Lei
    Zhao, Yong
    Everaert, Nadia
    Yi, Bao
    Zhang, Hongfu
    CRITICAL REVIEWS IN FOOD SCIENCE AND NUTRITION, 2023, 63 (12) : 1689 - 1706
  • [9] Gut-liver axis modulation of Panax notoginseng saponins in nonalcoholic fatty liver disease
    Yu Xu
    Ning Wang
    Hor-Yue Tan
    Sha Li
    Cheng Zhang
    Yibin Feng
    HEPATOLOGY INTERNATIONAL, 2021, 15 (02) : 350 - 365
  • [10] Gut-liver axis modulation of Panax notoginseng saponins in nonalcoholic fatty liver disease
    Yu Xu
    Ning Wang
    Hor-Yue Tan
    Sha Li
    Cheng Zhang
    Yibin Feng
    Hepatology International, 2021, 15 : 350 - 365